The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

Leukemia Research

Volumn 33, Issue 7, 2009, Pages 871-875

  Breccia, Massimo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bone metabolism; Glucose metabolism; Imatinib; Lipidic metabolism

Indexed keywords

BCR ABL PROTEIN; DASATINIB; GLUCOSE; IMATINIB; INSULIN; INTERFERON; LIPID; NILOTINIB; ORAL ANTIDIABETIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR;

ATHEROSCLEROSIS; BONE METABOLISM; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE METABOLISM; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REVIEW;

BONE AND BONES; GLUCOSE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIPID METABOLISM; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 67349253711     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.040     Document Type: Review

References (36)

1. Kantarjian H., and Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukaemia: using guidelines to make rational treatment choices. J Natl Compr Cnc Netw Suppl. 2 (2008) 37-42
2. Copland M., Jorgensen H.G., and Holyoake T.L. Evolving molecular therapy for chronic myeloid leukaemia: are we on target?. Hematology 10 (2005) 349-359
3. Schnadig I.D., and Blanke C.D. Gastrointestinal stromal tumors: imatinib and beyond. Curr Treat Options Oncol 7 (2006) 427-437
4. Quintas-Cardama A., and Cortes J.E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81 (2006) 973-988
5. Druker B.J., Guilhot F., O'Brien S., et al., IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
6. Hochhaus A., Druker B.J., Larson R.A., et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (2007) 110 [abstr. 25]
7. Apperley J.F. Mechanisms of resistance to imatinib in chronic myeloid leukaemia (part I and II). Lancet Oncol 8 (2007) 1018-1029
8. Boren J., Cascante M., Marin S., et al. (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276 (2001) 37747-37753
9. Gottschalk S., Anderson N., Hainz C., Eckhardt S.G., and Serkova N.J. Imatinib (STI571) mediated changes in glucose metabolism in human leukemia BCR-ABL positive cells. Clin Cancer Res 10 (2004) 6661-6668
10. Barnes K., McIntosh E., Whetton A.D., Daley G.Q., Bentley J., and Baldwin S.A. Chronic myeloid leukaemia: an investigation into the role of BCR-ABL induced abnormalities in glucose transport regulation. Oncogene 24 (2005) 3257-3267
11. Stroobants S., Goeminne J., Seegers M., et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 (2003) 2012-2020
12. Verweji J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumors with high dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
13. Tarn C., Skorobogatko Y.V., Taguchi T., Eisenberg B., von Mehren M., and Godwin A.K. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signalling dependent and independent mechanisms. Cancer Res 66 (2006) 5477-5486
14. Breccia M., Muscaritoli M., Aversa Z., Mandelli F., and Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukaemia patients responsive to treatment. J Clin Oncol 22 (2004) 4653-4655
15. Breccia M., Muscaritoli M., and Alimena G. Reduction of glycosilated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukaemia responsive to imatinib. Haematologica 90 (2005) ECR 21
16. Veneri D., Franchini M., and Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 352 (2005) 1049-1050
17. Dingli D., Wolf R.C., and vella A. Imatinib and type 2 diabetes. Endocr Pract 13 (2007) 126-130
18. Hamberg P., de Jong F.A., Boonstra J.G., van Doorn J., Verweij J., and Sleijfer S. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24 (2006) e30-e31
19. Haap M., Gallwitz B., Thamer C., et al. Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor. J Endocrinol Invest 30 (2007) 688-692
20. Hagerkvist R., Sandler S., Mokhtari D., and Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21 (2007) 618-628
21. Hagerkvist R., Jansson L., and Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 114 (2008) 65-71
22. Boucher P., Gotthardt M., Li W.P., Anderson R.G., and Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300 (2003) 329-332
23. Breccia M., Muscaritoli M., Gentilini F., et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukaemia patients resistant to imatinib. Leuk Res 31 (2007) 1770-1772
24. Breccia M., Muscaritoli M., Cannella L., Stefanizzi C., Frustaci A., and Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukaemia patient unresponsive to imatinib and nilotinib. Leuk Res 32 (2008) 1626-1628
25. Kadowaki T., and Kubota N. Protective role of imatinib in atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 801-803
26. Lassila M., Allen T.J., Cao Z., et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 935-942
27. Leppanen O., Rutanen J., Hiltunen M.O., et al. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 109 (2004) 1140-1149
28. Rocha A., Azevedo I., and Soares R. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis 10 (2007) 279-286
29. Gottardi M., Manzato E., and Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med 353 (2005) 2722-2723
30. Berman E., Nicolaides M., Maki R.G., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354 (2006) 2006-2013
31. Osorio S., Noblejas A.G., Duran A., and Steegmann J.L. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effects is associated with response. Am J Hematol 82 (2007) 394-395
32. Grey A., O'Sullivan S., Reid J.R., and Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 355 (2006) 2494-2495
33. O'Sullivan S., Nat D., Callon K., et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signalling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22 (2007) 1679-1689
34. Dewar A.L., Farrugia A.N., Condina M.R., et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 107 (2006) 4334-4337
35. El Hajj Dib I., Gallet M., Mentaverri R., Sevenet N., Brazier M., and Kamel S. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551 (2006) 27-33
36. Fitter S., Dewar A.L., Kostakis P., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 111 (2008) 2538-2547